FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321806202> ?p ?o ?g. }

• W2321806202 abstract "Introduction Drug discovery and development is an intense, lengthy and an interdisciplinary venture. Recently, a trend towards the use of in-silico chemistry and molecular modelling for computer-aided drug design has gained significant momentum. Insilico drug design skills are used in nanotechnology, molecular biology, biochemistry etc. The main benefit of the in-silico drug design is cost effective in research and development of drugs. There are wide ranges of software that are used in in-silico drug design, Grid computing, window based general PBPK/PD modelling software, PKUDDS for structure based drug design, APIS, JAVA, Perl and Python, in-silico drug design as well as software including software libraries. There are different techniques used in in-silico drug design visualization, homology, molecular dynamic, energy minimization molecular docking and QSAR etc. In-silico drug design can take part considerably in all stages of drug development from the preclinical discovery stage to late stage clinical development. Its exploitation in drug development helps in the selection of only a potent lead molecule and may thus thwart the late stage clinical failures; thereby a major diminution in cost can be achieved. This article gives an insight into all the aspects of in-silico drug design; its potential, drivers, current development and the future prospects. Conclusion In-silico methods have been of great importance in target identification and in prediction of novel drugs. Introduction Drug discovery and development is a very complicated, time consuming process and there are many factors responsible for the failure of different drugs such as lack of effectiveness, side effects, poor pharmacokinetics, and marketable reasons. The expenditure of this process has amplified ominously during the past thirty-four years. The Pharmaceutical Manufacturer’s Association received the industry average reports which have shown that the expenditure of drug development has enlarged from $4 million in 1962 to over $350 million in 1996. The improvement time of a drug from the first synthesis to its foreword in the market, has almost multiplied between 1960 and 1980. It has kept on comparatively unaffected since 1980 with a present time period of 9-13 years.1,4 According to pharmaceutical research and manufacturers the estimated cost of the complete drug discovery process is about US$880 million and takes up to 14 years from initial research stage to the successful marketing of an new drug in 2001.4 The recent figures of DiMasi at the Tufts Centre for Study of Drug Development (CSDD) is about US$802 million spread over 12 years, which was reported in 2003,4 while the Boston Consulting Group estimates the cost as $880 million over 15 years. At present the cost involved in the drug discovery process ranges f rom $800 million to $1.8 billion,5 The establishment of the Computer-Aided Drug Design (CADD) Centre was to endorse joint research among the scientists of various fields like biology, biophysics, structural biology and computational scientists.6 The main objective of CADDC entries is to start these partnerships that lead to the implementation of research projects to discover new compounds with the potential to be transformed into new therapeutic agents. The in-silico drug design is a vast field in which the different sides of basic research and practice are combined and inspire each other,7 modern techniques such as QSAR/QSPR, structure-based design, combinatorial library design, cheminformatics, bioinformatics and the increasing number of biological and chemical databases are used in the field. Furthermore, large numbers of the available tools provide a much developed basis for the design of ligands and inhibitors with preferred specificity.8 The aim of this review was to discuss the process of In-silico drug design." @default.
• W2321806202 created "2016-06-24" @default.
• W2321806202 creator A5003037848 @default.
• W2321806202 creator A5014822372 @default.
• W2321806202 creator A5046835809 @default.
• W2321806202 creator A5052148205 @default.
• W2321806202 creator A5052879108 @default.
• W2321806202 creator A5068134014 @default.
• W2321806202 date "2013-09-01" @default.
• W2321806202 modified "2023-10-01" @default.
• W2321806202 title "In-silico drug design: An approach which revolutionarised the drug discovery process" @default.
• W2321806202 cites W1508885706 @default.
• W2321806202 cites W1548843388 @default.
• W2321806202 cites W1969631507 @default.
• W2321806202 cites W2000868500 @default.
• W2321806202 cites W2001096106 @default.
• W2321806202 cites W2019476648 @default.
• W2321806202 cites W2022167638 @default.
• W2321806202 cites W2040198144 @default.
• W2321806202 cites W2063060349 @default.
• W2321806202 cites W2114520383 @default.
• W2321806202 cites W2121175754 @default.
• W2321806202 cites W2162740029 @default.
• W2321806202 cites W2329014669 @default.
• W2321806202 cites W265173753 @default.
• W2321806202 cites W2792455800 @default.
• W2321806202 cites W2949243165 @default.
• W2321806202 doi "https://doi.org/10.13172/2054-4057-1-1-1119" @default.
• W2321806202 hasPublicationYear "2013" @default.
• W2321806202 type Work @default.
• W2321806202 sameAs 2321806202 @default.
• W2321806202 citedByCount "34" @default.
• W2321806202 countsByYear W23218062022014 @default.
• W2321806202 countsByYear W23218062022017 @default.
• W2321806202 countsByYear W23218062022018 @default.
• W2321806202 countsByYear W23218062022019 @default.
• W2321806202 countsByYear W23218062022020 @default.
• W2321806202 countsByYear W23218062022021 @default.
• W2321806202 countsByYear W23218062022022 @default.
• W2321806202 countsByYear W23218062022023 @default.
• W2321806202 crossrefType "journal-article" @default.
• W2321806202 hasAuthorship W2321806202A5003037848 @default.
• W2321806202 hasAuthorship W2321806202A5014822372 @default.
• W2321806202 hasAuthorship W2321806202A5046835809 @default.
• W2321806202 hasAuthorship W2321806202A5052148205 @default.
• W2321806202 hasAuthorship W2321806202A5052879108 @default.
• W2321806202 hasAuthorship W2321806202A5068134014 @default.
• W2321806202 hasBestOaLocation W23218062021 @default.
• W2321806202 hasConcept C104317684 @default.
• W2321806202 hasConcept C111919701 @default.
• W2321806202 hasConcept C2775905019 @default.
• W2321806202 hasConcept C2780035454 @default.
• W2321806202 hasConcept C41008148 @default.
• W2321806202 hasConcept C54355233 @default.
• W2321806202 hasConcept C60644358 @default.
• W2321806202 hasConcept C70721500 @default.
• W2321806202 hasConcept C71924100 @default.
• W2321806202 hasConcept C74187038 @default.
• W2321806202 hasConcept C86803240 @default.
• W2321806202 hasConcept C98045186 @default.
• W2321806202 hasConcept C98274493 @default.
• W2321806202 hasConceptScore W2321806202C104317684 @default.
• W2321806202 hasConceptScore W2321806202C111919701 @default.
• W2321806202 hasConceptScore W2321806202C2775905019 @default.
• W2321806202 hasConceptScore W2321806202C2780035454 @default.
• W2321806202 hasConceptScore W2321806202C41008148 @default.
• W2321806202 hasConceptScore W2321806202C54355233 @default.
• W2321806202 hasConceptScore W2321806202C60644358 @default.
• W2321806202 hasConceptScore W2321806202C70721500 @default.
• W2321806202 hasConceptScore W2321806202C71924100 @default.
• W2321806202 hasConceptScore W2321806202C74187038 @default.
• W2321806202 hasConceptScore W2321806202C86803240 @default.
• W2321806202 hasConceptScore W2321806202C98045186 @default.
• W2321806202 hasConceptScore W2321806202C98274493 @default.
• W2321806202 hasIssue "1" @default.
• W2321806202 hasLocation W23218062021 @default.
• W2321806202 hasOpenAccess W2321806202 @default.
• W2321806202 hasPrimaryLocation W23218062021 @default.
• W2321806202 hasRelatedWork W1972678028 @default.
• W2321806202 hasRelatedWork W2003194288 @default.
• W2321806202 hasRelatedWork W201910722 @default.
• W2321806202 hasRelatedWork W2146211839 @default.
• W2321806202 hasRelatedWork W2152933096 @default.
• W2321806202 hasRelatedWork W2181705536 @default.
• W2321806202 hasRelatedWork W2605628782 @default.
• W2321806202 hasRelatedWork W2937687666 @default.
• W2321806202 hasRelatedWork W4283811329 @default.
• W2321806202 hasRelatedWork W4312723856 @default.
• W2321806202 hasVolume "1" @default.
• W2321806202 isParatext "false" @default.
• W2321806202 isRetracted "false" @default.
• W2321806202 magId "2321806202" @default.
• W2321806202 workType "article" @default.